
    
      Patients with AIS and abnormal glucose metabolism were enrolled in this prospective cohort
      study and divided into two groups. The HUK group were treated with urinary kallidinogenase
      and standard treatment, the control group received standard treatment. NIHSS scores, mRS
      scores and fasting blood glucose were evaluated and compared.
    
  